Immunome, Inc. discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Market Cap | 95.18 Million | Shares Outstanding | 12.203 Million | Avg 30-day Volume | 88.199 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.36 |
Price to Revenue | 9.997 | Debt to Equity | 0.0 | EBITDA | -21.933 Million |
Price to Book Value | 16.7692 | Operating Margin | -222.3705 | Enterprise Value | 11.248 Million |
Current Ratio | 3.955 | EPS Growth | 0.418 | Quick Ratio | 3.922 |
1 Yr BETA | -0.1718 | 52-week High/Low | 9.53 / 2.2 | Profit Margin | -215.4435 |
Operating Cash Flow Growth | 111.1342 | Free Cash Flow to Firm (FCFF) TTM | 64.706 Million | Free Cash Flow to Equity (FCFE) TTM | -16.419 Million |
Altman Z-Score | -1.0678 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-11-07 | 2 | |
|
0 | 2023-10-27 | 2 | |
|
0 | 2023-10-27 | 2 | |
LECHLEIDER ROBERT CHIEF MEDICAL OFFICER |
|
0 | 2023-10-27 | 2 |
SIEGALL CLAY B PRESIDENT AND CEO |
|
150,432 | 2023-10-02 | 2 |
|
60,840 | 2023-10-02 | 2 | |
|
1,279,914 | 2023-10-02 | 3 | |
TURNER BRUCE CHIEF STRATEGY OFFICER |
|
0 | 2023-10-02 | 2 |
HIGGINS JACK CHIEF SCIENTIFIC OFFICER |
|
0 | 2023-10-02 | 1 |
ROSETT MAX SVP OPERATIONS |
|
19,856 | 2023-10-02 | 1 |
|
0 | 2023-06-08 | 2 | |
|
0 | 2023-06-08 | 1 | |
|
0 | 2023-06-08 | 2 | |
SARMA PURNANAND D PRESIDENT AND CEO |
|
0 | 2023-06-08 | 1 |
|
0 | 2023-06-08 | 2 | |
STONEMAN SANDRA G. GENERAL COUNSEL AND CLO |
|
0 | 2023-06-08 | 1 |
GIESING DENNIS H CHIEF DEVELOPMENT OFFICER |
|
0 | 2023-06-08 | 1 |
ROCHE CORLEEN M. CHIEF FINANCIAL OFFICER |
|
0 | 2023-06-08 | 1 |
ROBINSON MATTHEW K CHIEF TECHNOLOGY OFFICER |
|
0 | 2023-06-08 | 1 |
|
3,750 | 2021-05-28 | 0 | |
MARCOU DIANE M INTERIM CFO |
|
0 | 2020-11-30 | 0 |
|
920,939 | 2020-10-06 | 0 | |
FITZGERALD RICHARD F CHIEF FINANCIAL OFFICER |
|
0 | 2020-10-01 | 0 |
MORIN MICHAEL CHIEF SCIENTIFIC OFFICER |
|
0 | 2020-10-01 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-09 16:25:27 -0500 | 2023-11-07 | A | 40,696 | a | 40,696 | direct | ||||||||||
2023-10-31 18:30:54 -0400 | 2023-10-27 | A | 400,000 | a | 400,000 | direct | ||||||||||
2023-10-31 18:32:27 -0400 | 2023-10-27 | A | 41,538 | a | 41,538 | direct | ||||||||||
2023-10-31 18:35:19 -0400 | 2023-10-27 | A | 41,538 | a | 41,538 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
IMMUNOME INC IMNM | 2023-12-01 22:15:04 UTC | -0.3074 | 5.6274 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 21:45:05 UTC | -0.3074 | 5.6274 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 21:15:04 UTC | -0.3074 | 5.6274 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 20:45:04 UTC | -0.3074 | 5.6274 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 20:15:04 UTC | -0.4779 | 5.7979 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 19:45:04 UTC | -0.4779 | 5.7979 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 19:15:04 UTC | -0.4779 | 5.7979 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 18:45:05 UTC | -0.4779 | 5.7979 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 18:15:03 UTC | -0.4779 | 5.7979 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 17:45:04 UTC | -0.6855 | 6.0055 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 17:15:03 UTC | -0.6855 | 6.0055 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 16:45:03 UTC | -0.6855 | 6.0055 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 16:15:04 UTC | -0.6855 | 6.0055 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 15:45:03 UTC | -0.6855 | 6.0055 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 15:15:05 UTC | -0.6855 | 6.0055 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 14:45:03 UTC | -1.6076 | 6.9276 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 14:15:04 UTC | -1.6076 | 6.9276 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 13:45:04 UTC | 0.8398 | 4.4802 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 13:15:04 UTC | 0.8398 | 4.4802 | 800000 |
IMMUNOME INC IMNM | 2023-12-01 12:45:04 UTC | 0.8398 | 4.4802 | 800000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|